Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $58.1 million.

  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) rose 210.73% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 210.73%. This contributed to the annual value of $56.8 million for FY2024, which is 207.71% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Shares Outstanding (Weighted Average) of $58.1 million as of Q3 2025, which was up 210.73% from $57.9 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Shares Outstanding (Weighted Average) high stood at $69.5 million for Q1 2021, and its period low was $54.6 million during Q1 2022.
  • In the last 5 years, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $56.8 million in 2024 and averaged $57.9 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 2155.2% in 2022, and later surged by 215.49% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $60.4 million in 2021, then fell by 9.36% to $54.8 million in 2022, then rose by 1.57% to $55.7 million in 2023, then grew by 2.08% to $56.8 million in 2024, then rose by 2.34% to $58.1 million in 2025.
  • Its last three reported values are $58.1 million in Q3 2025, $57.9 million for Q2 2025, and $57.5 million during Q1 2025.